# A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

> **NCT06280703** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 118 (estimated)

## Conditions studied

- Healthy
- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** LY3938577
- **DRUG:** Placebo
- **DRUG:** Insulin Degludec
- **DRUG:** Insulin Lispro
- **DRUG:** LY3938577
- **DRUG:** Placebo
- **DRUG:** Insulin Degludec
- **DRUG:** Basal Insulin
- **DRUG:** Lispro Prandial Insulin

## Key facts

- **NCT ID:** NCT06280703
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06280703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06280703, "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06280703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*